Dosing and monitoring of low-molecular-weight heparins in special populations

Pharmacotherapy

Volumn 21, Issue 2, 2001, Pages 218-234

  Duplaga, B A ^a   Rivers, C W ^b   Nutescu, E ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Dept of Pharmacy Practice ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA LMWH; ALPHAPARIN; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; ARDEPARIN; BLOOD CLOTTING FACTOR 10A; BOXOL; CERTOPARIN; DALTEPARIN; DECIPAR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONO EMBOLEX NM; NADROPARIN; NOVO LHN 1; PARNAPARIN; PHARMUKA 10169; PLAUCINA; RD 11885; REVIPARIN; RP 54563; TEDELPARIN; THROMBENOX; THROMBIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; TROPARIN; UNCLASSIFIED DRUG; WARFARIN; WY 90493 RD;

ADULT; AGED; ANTICOAGULATION; BLEEDING; BODY MASS; CARDIOVASCULAR RISK; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; INFANT; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; NEWBORN; OSTEOPOROSIS; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTICOAGULANTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CORONARY DISEASE; DRUG MONITORING; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE; PREGNANCY; VENOUS THROMBOSIS;

EID: 0035142879     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.2.218.34112     Document Type: Review

References (130)

1. Low molecular weight heparins: Current use and indications
2. Production and chemical processing of low molecular weight heparins
3. Low-molecular-weight heparins
4. Low molecular weight heparins: Practical considerations
5. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE)
6. Pharmacokinetics of low-molecular-weight heparins in animal models
7. Structural characteristics of low-molecular-weight heparins
8. Preclinical differentiation of low molecular weight heparins
9. Human pharmacokinetics of low molecular weight heparins
10. Differentiation of low molecular weight heparins: Applied and clinical considerations
11. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety
12. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
13. Heparin/low molecular weight heparin and tissue pathway factor inhibitor
14. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins. Biochemical considerations
15. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy
16. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban
17. Prolonged antithrombin activity of low-molecular-weight heparins: Clinical implications for the treatment of thromboembolic diseases
18. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin
19. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability
20. Identification of risk factors for bleeding during treatment of acute VTE with heparin or low molecular weight heparin
21. Treatment of deep vein thrombosis with low-molecular-weight heparins: A consensus statement of the Gessellschaft fur Thrombose-und Hamostaseforschung (GTH)
22. Clinical uses of low-molecular-weight heparins
23. Clinical differentiation of low molecular weight heparins
24. Prevention of VTE
25. Upper extremity deep venous thrombosis in cancer patients with venous access devices - Prophylaxis with a low-molecular-weight heparin (Fragmin)
26. Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity
27. Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery
28. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials
29. Prophylaxis of postoperative thromboembolism with low molecular weight heparins
30. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
31. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials
32. Low molecular weight heparin in prevention of perioperative thrombosis
33. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against VTE in patients undergoing elective hip replacement
34. Prevention of VTE in internal medicine with unfractionated heparin or low-molecular-weight heparins: A meta-analysis of randomised clinical trials
35. Venous thromboembolic prophylaxis in orthopedic surgery: Knee surgery
36. Deep-vein thrombosis: Prophylaxis in orthopedic surgery: Hip surgery
37. Comparison of two low-molecular-weight heparins for the prevention of postoperative vein thromboembolism after elective hip surgery. Reviparin study group
38. Prevention of deep venous thrombosis after hip replacement. Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin
39. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low molecular weight heparin
40. Comparison of 3, 000 IU aXa of the low molecular weight heparin certoparin with 5, 000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German thrombosis study group
41. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders
42. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders
43. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders
44. Low-molecular-weight heparin (enoxaparin) as prophylaxis against VTE after total hip replacement
45. Risk of deep-vein thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
46. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin)
47. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish prolonged prophylaxis (DaPP) study
48. Low molecular weight heparins in the outpatient management of VIE
49. Antithrombotic therapy for venous thromboembolic disease
50. Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222)
51. Therapeutic applications of subcutaneous low-molecular-weight heparin in acute venous thrombosis
52. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)
53. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY 216)
54. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study
55. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
56. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
57. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
58. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
59. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered in the home
60. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
61. Low-molecular-weight heparin in the treatment of patients with VTE
62. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
63. Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin
64. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
65. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
66. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-NOVO
67. Fragmin once or twice/day subcutaneously in the treatment of deep venous thrombosis of the leg
68. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once-or twice-daily low-molecular-weight heparin
69. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis
70. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis
71. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
72. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
73. Low molecular weight heparins (LMWH) in the treatment of patients with acute VTE
74. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute VTE: Results of a meta-analysis
75. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
76. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
77. The economic impact of treating deep venous thrombosis with low-molecular-weight heparin: Outcome of therapy and health economy aspects
78. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with VTE and contraindications to coumarin
79. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
80. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis
81. Randomized trial of subcutaneous low-molecular-weigh heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study
82. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study
83. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
84. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis
85. Low-molecular-weight heparins for acute coronary syndromes: An emergency medicine perspective
86. Antithrombotic agents in coronary artery disease
87. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
88. Comparison of two treatment durations (6 and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (Fraxiparine in ischaemic syndrome)
89. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
90. Low-molecular-weight heparin during instability in coronary artery disease
91. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
92. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
93. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
94. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial
95. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction
96. Low-molecular-weight heparins in the management of acute coronary syndromes
97. Principal view on dose adjustment of low molecular weight heparins
98. Factor Xa inhibition: Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage
99. Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery
100. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Treatment guidelines
101. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery
102. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
103. Low molecular weight heparin half life is prolonged in haemodialysed patients
104. Pharmacokinetic of a very low molecular weight heparin in chronic renal failure
105. Delayed elimination of enoxaparine in patients with chronic renal insufficiency
106. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure
107. Aging and VTE influence the pharmacodynamics of the anti-Xa and antithrombin activities of a low molecular weight heparin (nadroparin)
108. A comparison of adverse effects of enoxaparin in patients with renal insufficiency versus normal renal function
109. Treatment of pulmonary embolism by subcutaneous low-molecular-weight heparin in a hemodialysis patient
110. Current concepts: VTE during pregnancy
111. Current concepts of anticoagulant therapy in pregnancy
112. Deep venous thrombosis and pulmonary embolism
113. Anticoagulant therapy during pregnancy: An update
114. Anticoagulation with low-molecular-weight heparin during pregnancy, no. 211, November 1998
115. Low-molecular-weight heparins in pregnancy
116. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy
117. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy
118. Venous thrombo-embolic complications (VTE) in children: First analyses of the Canadian Registry of VTE
119. Thrombosis in the young: Epidemiology and risk factors. A focus on venous thrombosis
120. Guidelines for antithrombotic therapy in pediatric patients
121. Antithrombotic therapy in children
122. Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
123. Anticoagulation therapy in pediatric patients with sinovenous thrombosis
124. A nomogram to establish therapeutic levels of the low-molecular-weight heparin (LMWH), clivarine in children requiring treatment for VTE
125. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: A report on 48 cases